A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

153

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

April 8, 2020

Study Completion Date

April 8, 2020

Conditions
Advanced Solid Tumors
Interventions
DRUG

SRA737, gemcitabine, cisplatin

DRUG

SRA737, gemcitabine

Trial Locations (20)

28040

START Madrid, Madrid

28041

Hospital Universitario 12 de Octobre, Madrid

29010

Hospital Universitario Virgen de la Victoria, Málaga

46010

Biomedical Research Institute INCLIVA, Valencia

08035

Hospital Universitario Vall d'Hebron, Barcelona

08036

Hospital Clinic de Barcelona, Barcelona

SM2 5PT

Royal Marsden Hospital, Sutton

BT9 7AB

Belfast City Hospital, Belfast

OX3 7LE

Oxford University Hospitals, Headington

CF14 2TL

Velindre Cancer Centre, Cardiff

CH63 4JY

The Clatterbridge Cancer Centre, Bebington

G12 0YN

The Beatson West of Scotland Cancer Centre, Glasgow

LS9 7TF

Leeds Teaching Hospital of St James University Hospital, Leeds

LE1 5WW

University Hospital of Leceister NHS TRUST, Leicester

SE1 9RT

Guy's and St Thomas', London

W1G 6AD

Sarah Cannon Research Institute, London

WC1E 6BT

University College London, London

M20 4BX

The Christie NHS Foundation Trust, Manchester

NE7 7DN

Freeman Hospital, Newcastle upon Tyne

S10 2SJ

Sheffield Teaching Hospitals, Sheffield

All Listed Sponsors
lead

Sierra Oncology LLC - a GSK company

INDUSTRY

NCT02797977 - A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects | Biotech Hunter | Biotech Hunter